The Valley Desk

NCT02785952 · Interventional trial

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Overall registry status Active not recruiting

Phase 3

Conditions Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov